GSK PLC Sponsored ADR (NYSE:GSK) Stock Holdings Lowered by Mesirow Financial Investment Management Inc.

Key Points

• Mesirow Financial Investment Management Inc. has reduced its holdings in GSK PLC by 50%, owning 16,714 shares after selling 16,692 shares during the first quarter.
• GSK reported earnings of $1.23 per share for the last quarter, exceeding analysts' expectations and showing a year-over-year revenue increase of 1.3%.
• The company has declared a quarterly dividend of $0.4206 per share, representing an annualized yield of 4.5%, with a payout ratio of 79.17%.

Mesirow Financial Investment Management Inc. reduced its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 50.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,714 shares of the pharmaceutical company's stock after selling 16,692 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in GSK were worth $647,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new stake in shares of GSK in the 1st quarter worth approximately $36,000. First Pacific Financial bought a new stake in shares of GSK in the 1st quarter worth approximately $45,000. CX Institutional bought a new stake in shares of GSK in the 1st quarter worth approximately $46,000. Finally, HM Payson & Co. raised its holdings in shares of GSK by 79.7% in the 1st quarter. HM Payson & Co. now owns 1,308 shares of the pharmaceutical company's stock worth $51,000 after purchasing an additional 580 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK opened at $37.15 on Friday. The company's 50 day moving average price is $38.98 and its 200 day moving average price is $37.63. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a market capitalization of $75.83 billion, a PE ratio of 17.20, a PEG ratio of 1.59 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 50.68%. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same period last year, the business posted $0.43 EPS. GSK's revenue was up 1.3% compared to the same quarter last year. Research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.5%. GSK's dividend payout ratio is 79.17%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GSK. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of "Hold" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.